Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis
Toshiki KunoTomohiro FujisakiSatoshi ShojiYuki SahashiYusuke TsugawaMasao IwagamiHisato TakagiAlexandros BriasoulisPierre DeharoThomas CuissetAzeem LatibShun KohsakaDeepak L. BhattDivision of Cardiology,Montefiore Medical Center,Albert Einstein College of Medicine,New York,NY (T.K.,A.L.).Department of Medicine,Icahn School of Medicine at Mount Sinai,Mount Sinai Beth Israel,New York,NY (T.K.).Department of Cardiovascular Medicine,Graduate School of Medical Sciences,Kumamoto University,Japan (T.F.).Department of Medicine,Icahn School of Medicine at Mount Sinai,Mount Sinai Morningside and West,New York,NY (T.F.).Department of Cardiology,Keio University School of Medicine,Tokyo,Japan (S.S.,S.K.).Department of Cardiology,Gifu University,Japan (Y.S.).Division of General Internal Medicine and Health Services Research,David Geffen School of Medicine at UCLA,Los Angeles,CA (Y.T.).Department of Health Policy and Management,UCLA Fielding School of Public Health,Los Angeles,CA (Y.T.).Department of Health Services Research,University of Tsukuba,Japan (M.I.).Department of Cardiovascular Surgery,Shizuoka Medical Center,Japan (H.T.).Division of Cardiology,Heart Failure and Transplantation,University of Iowa' Iowa City (A.B.).Département de Cardiologie,CHU Timone,Marseille,France (P.D.,T.C.).Center for Cardiovascular and Nutrition Research,INSERM,INRA (P.D.,T.C.),Aix-Marseille Université,France.Faculté de Médecine (P.D.,T.C.),Aix-Marseille Université,France.Brigham and Women's Hospital Heart and Vascular Center,Harvard Medical School,Boston,MA (D.L.B.).
DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.122.011990
2022-07-28
Abstract:The benefit of dual antiplatelet therapy (DAPT) for reducing ischemic events is greatest in the early period of acute coronary syndrome, and recent randomized controlled trials have investigated the unguided de-escalation strategy of changing potent P2Y 12 inhibitors to less potent or reduced-dose P2Y 12 inhibitors 1 month after acute coronary syndrome. However, it remains unclear which strategy is more effective and safer: the uniform unguided de-escalation strategy versus the personalized guided selection of DAPT with genotype or platelet function tests. PubMed, EMBASE, and Cochrane Central were searched for articles published from database inception to September 10, 2021. Randomized controlled trials investigating DAPT using clopidogrel, low-dose prasugrel, standard-dose prasugrel, ticagrelor, unguided de-escalation strategy, and guided selection strategy for patients with acute coronary syndrome were included. Hazard ratios and relative risk estimates were extracted from each study. The estimates were pooled using a random-effects network meta-analysis. The primary efficacy outcome was major adverse cardiovascular events, defined as a composite of cardiovascular death, myocardial infarction, or stroke. The primary safety outcome was major or minor bleeding. Secondary outcomes were all-cause death, cardiovascular death, myocardial infarction, stroke, stent thrombosis, and major bleeding. This study included 19 randomized controlled trials with 69 746 patients. Compared with guided selection of DAPT, unguided de-escalation of DAPT was associated with a decreased risk of the primary safety outcome (hazard ratio, 0.48 [95% CI, 0.33–0.72]) without increased risks of major adverse cardiovascular events (hazard ratio, 0.82 [95% CI, 0.53–1.28]) or any secondary outcomes. The results were similar when the guided selection strategy was divided into platelet function–guided and genotype-guided strategies. Compared with guided selection of DAPT, unguided de-escalation of DAPT decreased bleeding without increasing ischemic events in patients after acute coronary syndrome. If a strategy of de-escalation is chosen, these findings do not support the routine use of personalized guiding tests. URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42021273082. Download figure Download PowerPoint